These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 26285606)

  • 21. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding and targeting prostate cancer cell heterogeneity and plasticity.
    Tang DG
    Semin Cancer Biol; 2022 Jul; 82():68-93. PubMed ID: 34844845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling.
    Luo J; Ok Lee S; Liang L; Huang CK; Li L; Wen S; Chang C
    Oncogene; 2014 May; 33(21):2768-78. PubMed ID: 23792449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stem cells in genetically-engineered mouse models of prostate cancer.
    Shibata M; Shen MM
    Endocr Relat Cancer; 2015 Dec; 22(6):T199-208. PubMed ID: 26341780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
    Margiotti K; Wafa LA; Cheng H; Novelli G; Nelson CC; Rennie PS
    Mol Cancer; 2007 Jun; 6():38. PubMed ID: 17553164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
    Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
    Desiniotis A; Schäfer G; Klocker H; Eder IE
    Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.
    Tian J; Lee SO; Liang L; Luo J; Huang CK; Li L; Niu Y; Chang C
    J Biol Chem; 2012 Nov; 287(47):39954-66. PubMed ID: 23012352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen action and metabolism in prostate cancer.
    Green SM; Mostaghel EA; Nelson PS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
    Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G
    Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
    Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
    Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics.
    Comstock CE; Knudsen KE
    Cell Cycle; 2007 Jun; 6(11):1307-13. PubMed ID: 17568191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
    Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
    Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
    Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.
    Kim Y; Kim J; Jang SW; Ko J
    Oncogene; 2015 Jan; 34(2):226-36. PubMed ID: 24441043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.
    Lee SO; Ma Z; Yeh CR; Luo J; Lin TH; Lai KP; Yamashita S; Liang L; Tian J; Li L; Jiang Q; Huang CK; Niu Y; Yeh S; Chang C
    J Mol Cell Biol; 2013 Feb; 5(1):14-26. PubMed ID: 22831834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.